Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Comparison of care patterns for hospitalized immune-related adverse events (irAEs) between melanoma patients on combination immune checkpoint inhibitor (ICI) therapy versus ICI monotherapy.
Authors
RuiQui Chen
Princess Margaret Cancer Centre, Toronto, ON, Canada
RuiQui Chen, Elliot Charles Smith, Sze Wah Samuel Chan, Katrina Hueniken, M. Catherine Brown, Habeeb Majeed, Kendra Ross, Diana Gray, Wei Xu, David Hogg, Srikala S. Sridhar, Adrian G. Sacher, Natasha B. Leighl, Monika K. Krzyzanowska, Marcus O. Butler, Geoffrey Liu, Lawson Eng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune-related Adverse Events
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 85)
DOI
10.1200/JCO.2019.37.8_suppl.85
Abstract #
85
Poster Bd #
D10
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Real-world characterization of patients with cancer admitted with immune-related adverse events (irAEs).
First Author: Lawson Eng
Poster
2016 ASCO Annual Meeting
Toxicity associated with ipilimumab and nivolumab (Ipi+Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP).
First Author: Claire Frances Friedman
Poster
2023 ASCO Annual Meeting
Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer.
First Author: Jarushka Naidoo
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla